top of page
⮜ BACK
cropped-lol.jpg
  • x.com
  • EMAIL
  • PHONE
Image by National Institute of Allergy and Infectious Diseases

Reviews

Progress and challenges towards targeted delivery of cancer therapeutics
Special delivery: targeted therapy with small RNAs
Polysaccharides as building blocks for nanotherapeutics

2025-2026

  1. Martins C, Mitchell J.M, Peer D, Perrie Y, Siegwart DJ, Alonso M.J, Aparicio‑Blanco J. (2026) RNA Delivery Dilemma—Lipid Versus Polymer Platforms. Drug Delivery and Translational Research  PDF

  2. Kovačič T, Haas  H,  Stotsky-Oterin L, Štrancar A,  Bren  U, Peer D. (2025) The Impact of Chemical Reactivity on the Quality and Stability of RNA–LNP pharm. Nature Review Chemistry. PDF

  3. Herrara V, Tarab-Ravski D, Chauhan S.C, Narang N, Islam M.M, Peer D, Prasad R, Yallapu M.M. (2025) Nanotechnology Strategies for Endometrium Health: Are We on the Right Track? Bioactive materials 54: 423-449. PDF

  4. Aernout  I, Verbeke  R, Thery F, Willems P, Elia  Y, De Smedt  S.C,Rappuoli  R, Peer  D, Impens  F, Lentacker  I  (2025) Challenges and Opportunities in mRNA Vaccine Development Against Bacteria.  Natue Immunology 10:1816-1828  PDF

  5. Dekel Y, Cohen S, Peer D. In memoriam: Professor Rimona Margalit (1941–2024). J. Control Release 385: 113994.  PDF

  6. Peer D and JCR editors (2025) Effective Communication with JCR Editors in the Peer Review Process. J. Control Release. 385, 113973. PDF

  7. Prasad R, Ghosh A, Patel V, Peng B, Mendes BB, Win EHA, Delogu LG, Wong JY, Pischel KJ, Bellare JR, Bar-Shir A, Thakor AS, Parak WJ, Bhujwalla ZM, Zhang YS, Kommineni N, Rotello VM, Cai W, Lammers T, Odom TW, Padmanaban G, Peer D, Lovell JF, Srivastava R, Langer R, Conde J. (2025) Voices of Nanomedicine: Blueprint Guidelines for Collaboration in Addressing Global Unmet Medical Needs. ACS NanL​​

​​2023-2024

  1. Chulanova Y, Breier D, Peer D (2024) Delivery of Genetic Medicines for Muscular Dystrophies. Cell Rep Med. 101885. PDF

  2. Sharma P, Breier D, Peer D (2024) Immunogenic Amines on Lipid Nanoparticles. Nat Biomed Eng.  8(11), 1332-1333. PDF 

  3. Tarab-Ravski D, Stotsky-Oterin L, Elisha A, Kundoor GR, Ramishetti S, Hazan-Halevy I, Haas H, Peer D (2024) The Future of Genetic Medicines Delivered via Targeted Lipid Nanoparticles to Leukocytes. J Control Release. 376:286-302. PDF

  4. Masarwy R, Stotsky-Oterin L, Elisha A,  Hazan-Halevy I, Peer D (2024) Delivery of Nucleic Acid Based Genome Editing Platforms via Lipid Nanoparticles: Clinical Applications. ADDR 211(115359) 1-21. PDF

  5. Qassem S, Breier D, Naidu G.S, Hazan-Halevy I, Peer D (2024) Unlocking the Therapeutic Potential of Locked Nucleic Acids Through lipid Nanoparticle Delivery. Molecular Therapy: Nucleic Acids 35, 1-12. PDF 

  6. Chatterjee S, Edo Kon, Sharma P,  Peer D (2024) Endosomal Escape: A Bottleneck for LNP-Mediated Therapeutics. PNAS 121(11) e2307800120. PDF

  7. Sharma P, Hoorn D, Aitha A,  Breier D, Peer D (2024) The Immunostimulatory Nature of mRNA-lipid Nanoparticles. ADDR 205(115175):1-22. PDF

  8. Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D (2023) Targeting Cancer with mRNA-Lipid Nanoparticles: Key Considerations and Future Prospects. Nat Rev Clin Oncol. 20(11):739-754. PDF

  9. Rampado R, Peer D. (2023) Design of Experiments in the Optimization of Nanoparticle-Based Drug Delivery Systems. J Control Release .358 398–419. PDF

  10. Hazan-Halevy I, Kon E, Stotsky-Oterin L, Peer D (2023) mRNA Vaccines: Using Tiny Particles to Fight Viruses. Frontiers for Young Minds. PDF

  11. Veiga N, Diesendruck Y, Peer D (2023) Targeted Nanomedicine: Lessons Learned and Future Directions. J Control Release S0168-3659. PDF

  12. Breier D, Peer D (2023) Genome Editing in Cancer: Challenges and Potential Opportunities. Bioactive Material 21: 394-402. PDF

2021-2022

  1. Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, Peer D, Tao W. (2022) Nanotechnology-Based Strategies Against SARS-CoV-2 Variants. Nat Nanotechnol. PDF

  2. Tarab-Ravski D, Stotsky-Oterin L, Peer D. (2022) Delivery Strategies of RNA Therapeutics to Leukocytes. J. Control. Release. 342: 362-371. PDF

  3. Gutkin A, Rosenblum D and Peer D. (2021) RNA Delivery with a Human Virus-Like Particle. Nature Biotechnology. PDF 

  4. Kon E, Elia U, Peer D (2022) Principles of Designing an Optimal mRNA Lipid Nanoparticle Vccine. Current Opinion in Biotechnology 73: 1-8. PDF

  5. Schlich M, Palomba R,  Costabile G, Mizrahy S, Pannuzzo M, Peer D, Decuzzi P (2021) Cytosolic Delivery of Nucleic Acids: The Case of Ionizable Lipid Nanoparticles. Bioenjeenering and Translational Medicine 6(2):e10213. PDF

  6. Decuzzi P, Peer D, Mascolo DD, Palange AL, Manghnani PN, Moghimi SM, Farhangrazi ZS, Howard KA, Rosenblum D, Liang T, Chen Z, Wang Z, Zhu JJ, Gu Z, Korin N, Letourneur D, Chauvierre C, van der Meel R, Kiessling F, Lammers T. (2021) Roadmap on Nanomedicine. Nanotechnology 32(1):012001. PDF​

2019-2020

  1. Dammes N, Peer D (2020) Paving the Road for RNA Therapeutics. Trends in Pharmacological Sciences 41(10):755-775. PDF

  2. Rosenblum D, Gutkin A, Dammes N,  Peer D (2020) Progress and Challenges Towards CRISPR/Cas Clinical Translation. Adv Drug Deliv Rev. S0169(20): 30080-30086. PDF

  3. Veiga N,  Diesendruck Y, and Peer D (2020) Targeted Lipid Nanoparticles for RNA Therapeutics and Immunomodulation in leukocytes. Adv Drug Deliv Rev. S0169(20): 30022-30033. PDF

  4. Dammes N, and Peer D (2020) Monoclonal Antibody-Based Molecular Imaging Strategies and Theranostic Opportunities. Theranostics. 10(2):938-955. PDF

  5. Moghimi SM, and Peer D (2019) Reprogramming the Lymphocyte Axis for Immunotherapy. Advanced Drug Delivery Reviews 141:1–2. PDF

  6. Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, and Michelassi F (2019) Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis. 25:S24-S30. PDF

  7. Granot-Matok Y,  Kon E, Dammes N, Mechtinger G, and Peer D (2019) Therapeutic mRNA Delivery to Leukocytes. Journal of Controlled Release 305, 165-175. PDF

  8. Mizrahy S, Gutkin A, Decuzzi P, and Peer D (2019) Targeting Central Nervous System Pathologies with Nanomedicines. J. Drug Target. 27(5-6):542-554. PDF​

2017-2018

  1. Ramishetti S, and Peer D (2018) Engineering Lymphocytes with RNAi. Adv Drug Deliv Rev. 141:55-66.  PDF

  2. Gutkin A, and Peer D (2018) Gene Silencing in the Right Place at the Right Time. Mol Ther. 5;26(12):2875.  PDF

  3. Rosenblum D, Joshi N, Tao W, Karp J.M,  and Peer D (2018) Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics. Nature Communications 9:1-12. PDF

  4. Granot Y,  and Peer D (2017) Delivering the Right Message: Challenges and Opportunities in Lipid Nanoparticles-Mediated Modified mRNA Therapeutics- An Innate Immune System Standpoint. Semin Immunol 34:68-77. PDF

  5. Rietwyk S, and Peer D (2017) Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 11:7572−7586. PDF

  6. Alvarez MM, Aizenberg J, Analoui M, Andrews AM, Bisker G, Boyden ES, Kamm R.D, Karp JM, Mooney DJ, Oklu R, Peer D, Stolzoff M,  Strano MS, Trujillo-de Santiago G, Webster TJ, Weiss PS, and Khademhosseini A (2017) Emerging Trends in Micro- and Nanoscale Technologies in Medicine: from Basic Discoveries to Translation. ACS Nano 11:5195-5214. PDF

  7. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, and Peer D (2017) Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Molecular Therapy 25:1491-1500. PDF

  8. Mizrahy S, Hazan-Halevy I, Landesman-Milo D,  and  Peer D (2017) Advanced strategies in Immune Modulation of Cancer using Lipid-Based Nanoparticles. Frontiers in Immunology 8:69. PDF

  9. Anchordoquy TJ,  Barenholz Y,  Boraschi D, Chorny M,  Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS,  Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L,  Park JH,  Peer D, Ruoslahti E, Serkova NJ, and Simber D (2017) Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ASC Nano.  PDF

  10. Ng BD, and Peer D (2017) Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. Molecular Therapy 25:5-7. PDF​

2015-2016

  1. Hazan-Halevy I, Landesman-Milo D, Rosenblum D, Mizrahy S, Ng BD, and Peer D (2016) Immunomodulation of Hematological Malignancies using Oligonucleotides Based-Nanomedicines. Journal of Controlled Release, 244:149-156. PDF

  2. Gutkin A, Cohen ZR, and Peer D (2016) Harnessing Nanomedicine for Therapeutic Intervention in Glioblastoma. Expert Opinion on Drug Delivery ISSN: 1744-7593:1573-1582. PDF

  3. Ramishetti S, Landesman-Milo D, and Peer D (2016) Advances in RNAi Therapeutic Delivery to Leukocytes Using Lipid Nanoparticles. J Drug Target. 24(9):780-786. PDF

  4. Singh MS, and Peer D (2016) siRNA Delivery: Current Trends and Future Perspectives.  Ther Deliv. 51-53. PDF

  5. Singh MS, Peer D (2016) RNA Nanomedicines: the Next Generation of Drugs? Current Opinion in Biotechnology 28-34. PDF

  6. Landesman-Milo D, and Peer D (2016) Transforming Nanomedicines from Lab-Scale Production to Novel Clinical Modality. Bioconjug Chem. 27(4):855-862. PDF

  7. Moyano DF, Liu Y., Peer D and Rotello VM (2016) Modulation of Immune Response Using Engineered Nanoparticle Surfaces. Small 12(1),76-82. PDF

  8. Moghimi SM, Hunter AC, and Peer D (2016) Platelet Mimicry: The emperor’s New Clothes? Nanomedicine 12:245-248. PDF

  9. Landesman-Milo D, Ramishetti S, and Peer D (2015) Nanomedicine as an Emerging Platform for Metastatic Lung Cancer Therapy. Cancer and Metastasis Reviews 34(2):291-301. PDF

  10. Ganoth A, Cohen K.M, and Peer D (2015) Overcoming Multidrug Resistance with Drug Delivery Strategies. Expert Opin Drug Deliv.  12(2):223-238. PDF

2013-2014

  1. Peer D (2014) Precision medicine – delivering the goods? Cancer Letters 352:2-3. PDF

  2. Goldsmith M, Abramovitz L, and Peer D (2014) Precision Nanomedicine in Neurodegenerative Diseases. ACS Nano 8(3):1958-1965. PDF

  3. Bogart K., Pourroy G, Murphy CJ, Puntes VF, Pellegrino T, Rosenblum D, Peer D*, and Lévy R* (2014) Nanoparticles for Imaging, Sensing, and Therapeutic Intervention. ACS Nano 8(4):3107–3122. *denotes equal contribution. PDF

  4. Peer D (2014) Harnessing RNAi Nanomedicine for Precision Therapy. Molecular and Cellular Therapies 2(5):2-11.PDF

  5. Rosenblum D, and Peer D (2014) Omics-Based Nanomedicine: The Future of Personalized Oncology. Cancer Letters. 352, 126-136. PDF

  6. Peer D, Giannechi N. and Luo D (2013) Nanoparticles in Biology. Journal of Materials Chemistry . PDF

  7. Mizrahy S, Landesman-Milo D, and Peer D (2013) Sweet Fairytale: Carbohydrates as Backbones for Glyconanomedicine. Israel Journal of Chemistry 53 (9-10):616-629. PDF

  8. Howard KA. and Peer D (2013) Providing the Full Picture: a Mandate for Standardizing Nanoparticle-Based Drug Delivery.Nanomedicine (Lond). 8(7):1031-1033. PDF

  9. Peer D (2013) A Daunting Task: Manipulating Leukocyte Function with RNAi. Immunol Rev. 253:185–197. PDF​

2006-2012

  1. Vorup-Jensen T, and Peer D (2012) Nanotoxicity and the Importance of Being Earnest. Adv. Drug Deliv. Rev. 64 (15):1661-1662.PDF

  2. Daka A, and Peer D (2012) RNAi-Based Nanomedicines for Targeted Personalized Therapy. Adv. Drug Deliv. Rev. 64(13), 1508-1521. PDF

  3. Peer D (2012) Immunotoxicity Derived from Manipulating Leukocytes with Lipid-based Nanoparticles. Adv. Drug Deliv. Rev. 64 (15):1738–1748. PDF

  4. Barenholz Y, and Peer D (2012) Liposomes, lipid Biophysics, and Sphingolipid Research: from Basic to Translational Research. Chemistry & Physics of Lipids 165:363-364. PDF

  5. Barenholz Y, and Peer D (2012) Liposomes and other Assemblies as Drugs and Nano-Drugs: from basic and Translational Research to the Clinics. Journal of Controlled Release 160(2):115-116. PDF

  6. Landsman–Milo D, and Peer D (2012) Altering the Immune Response with liposomes. Journal of Controlled Release 161:600-608. PDF

  7. Mizrahy S, and Peer D (2012). Polysaccharides as Building Blocks for Nanotherapeutics. Chem. Soc. Rev. 41:2623–2640. PDF

  8. Goldsmith M, Mizrahy S, and Peer D (2011) Grand Challenges in Modulating the Immune Response with RNAi Nanomedicines. Nanomedicine 6(10):1771-1785. PDF

  9. Peer D, and Lieberman J (2011) Special Delivery: Targeted Therapy with Small RNAs. Gene therapy 18(12):1127-1133. PDF

  10. Elfakess R, and Peer D (2010) Overcoming RNAi Transduction in Leukocytes using Targeted and Stabilized Nanoparticles. IDrugs 13(9):626-631. PDF

  11. Weinstein S, and Peer D (2010) RNAi Nanomedicines: Challenges and within Opportunities the Immune System. Nanotechnology 21(23), 232001:1-13. PDF

  12. Peer D (2010) Induction of Therapeutic Gene Silencing in Leukocyte-Implicated Diseases by Targeted and Stabilized Nanoparticles: a mini-review. Journal of Controlled Release. 148(1):63-68. PDF

  13. Kedmi R, and Peer D (2009) RNAi Nanoparticles in the Service of Personalized Medicine. Nanomedicine 4(8):853-855. PDF

  14. Peer D, and Shimaoka M (2009) Systemic siRNA Delivery to Leukocyte-Implicated Diseases. Cell Cycle 8:853-859. PDF

  15. Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007) Nanocarriers as an Emerging Platform for Cancer Therapy. Nature Nanotechnology 2:751-760. PDF

  16. Klausner EA, Peer D, Chapman RL, Multack RF, and Andurkar SV. (2007) Corneal Gene Therapy. Journal of Controlled Release 124(3):107-133. PDF

  17. Peer D, and Margalit R (2006) Fluoxetine and Reversal of Multidrug Resistance. Cancer Letters 237:180-187. PDF

bottom of page